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Accepted 14 November 2012AbstractObjective: To assess the factors associated with future pregnancy and successful delivery in women who were treated for uterine adenomyoma
with combination (surgicalemedical) therapy using ultramini- or mini-laparotomy conservative surgery and gonadotropin-releasing hormone
agonist.
Materials and Methods: One hundred and two women were evaluated. Items for analysis included: age, body mass index, and conception
history; clinical symptoms of dysmenorrhea and menorrhagia; tumor location and preoperative serum level of cancer antigen 125 (CA125); the
intraoperative findings of the weight of the removed tumor, and the uterine cavity opening.
Results: After excluding those patients using contraception or searching for an assisted reproductive technique, a total of 56 women were
enrolled for analysis. Twenty-three (41.1%) women had 27 clinical pregnancies after 3 years of follow-up; 15 went on to deliver a healthy live-
born child; two delivered preterm but healthy babies; seven had elective abortions; four had spontaneous abortions; and one had an ectopic
pregnancy. The women who had a successful delivery during the 3-year follow-up after treatment tended to be younger, with a lower body mass
index, lower baseline analgesic usage score, and lower preoperative serum level of CA125, be nulliparous, and with an adenoma in an anterior
location. The linear regression model showed that age and baseline analgesic usage score were independent predictors of successful delivery and
accounted for 56.5% of the total variance related to successful delivery.
Conclusion: Age was an important factor associated with future successful delivery, therefore, caution should be taken in considering the
maintenance of future fertility in older women treated with surgicalemedical therapy.
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Uterine adenomyosis and its variant uterine adenomyoma
(relatively localized characteristics of focal adenomyosis) not
only present dysmenorrhea, menorrhagia, and chronic pelvic
pain, but also may contribute to subfertility [1e4]. Hysterec-
tomy is often considered the optimal treatment for uterus-
related pathology, including adenomyosis, adenomyoma,
myoma, and other diseases [5e9]. In addition, adenomyosis or
adenomyoma penetrate into the normal myometrium diffusely,
rendering their complete removal difficult and the possibility
of recurrence high [10e12]. However, many women with
uterine pathology have a strong desire to preserve the uterus,
for which alternative treatment options are available [13e17].
Among these options, medical therapy, which may be the
least invasive and most acceptable strategy, includes the use of
prostaglandin inhibitors, oral contraceptive pills, progestogens,
danocrine, and gonadotropin-releasing hormone (GnRH) ago-
nist [18e21]. Unfortunately, the effect of these medical treat-
ments is often transient and some patients cannot tolerate the
side effects of long-term medical treatment; furthermore, the
symptoms (especially pain) of uterine adenomyoma nearly
always reappear when discontinuing medication [2].
For those who are refractory to or unsuitable for long-term
medical treatment, conservative surgical approaches, including
endomyometrial ablation, laparoscopic myometrial electro-
coagulation, laparoscopic cytoreductive surgery, and excision
of the myometrial adenomyoma through exploratory laparot-
omy, have been tried, although they are considered to be more
invasive and radical treatments [22e24]. It is disappointing
that the effects have been varied, and the highest effective rate
was reported to be 50%. In addition, and of most importance,
follow-up assessment has been of short duration and the long-
term effect is not clear, although one report showed a suc-
cessful pregnancy outcome in one patient [23].
As a result of the transient effect and possible poor com-
pliance with medical therapy, and the only 50% effectiveness of
the above-mentioned surgical approaches in managing uterine
adenomyoma, the combination of conservative surgery and
medical treatment with either GnRH agonist or danazol (sur-
gicalemedical treatment) has been tried [24e28]. The current
study was a further follow-up of 102 women with uterine
adenomyoma treated with a combination of ultramini- or mini-
laparotomy conservative surgery and six courses of GnRH
agonist [28]. Our goal was to focus on the fertility outcome of
patients who did not receive reproductive assistance.
This may be one of the largest series to search for the
critical factors related to the future pregnancy rate of patients
who receive combination (surgicalemedical) treatment for
adenomyoma.
Materials and methodsPatientsThe detailed information of this study has been published
before [28]. The protocol was first explained to all prospectiveparticipants after the institutional review board approval;
thereafter, written informed consent was obtained from those
actually enrolled in this study. Participants were eligible for
the study if they were between 20 and 45 years of age. If they
had severe dysmenorrhea with or without menorrhagia and
a firm, enlarged uterus, they were given a tentative diagnosis
of uterine adenomyoma and/or possible adenomyosis. The
preoperative evaluation comprised a routine biochemistry
workup, including cancer antigen 125 (CA125) in the luteal
phase of every woman, complete blood count, and ultrasound
examination. All patients received both transvaginal and
abdominal ultrasound evaluations, with the exception of pa-
tients who denied ever having had a sexual experience, who
were evaluated by abdominal ultrasound only.
The diagnosis of adenomyoma was confirmed by final pa-
thology. Patients with other significant diseases of the pelvic
organs, and/or other medical or surgical illnesses were
excluded. Patients with the following diseases also were
excluded: (1) medical or other chronic illness [e.g., anemia
due to other causes, including hereditary anemia, blood loss
from the upper or lower gastrointestinal tracts by stool routine
and history (no occult blood), liver, renal, endocrine, or met-
abolic disorders, or poor nutrition status]; (2) a coexistence of
extensive pelvic or uterine diseases (e.g., extensive endome-
triosis, ovarian endometrioma, or endometriosis associated
with obliteration of the cul-de-sac, hydrosalpinx, extensive
pelvic adhesion, pelvic inflammatory diseases, or multiple
uterine fibroids). The exclusion criteria were use of a contra-
ception method, searching for an assisted reproductive tech-
nique, and laparoscopic surgery for removal of adenomyoma.
Our study was conducted to determine the factors asso-
ciated with the future pregnancy and successful delivery of
women with uterine adenomyoma who were treated with
a combination of ultramini- or mini-laparotomy conservative
surgery and GnRH agonist therapy. Therefore, only women
treated with this combination therapy who intended to become
pregnant after treatment, and who were not using a contra-
ception method or searching for an assisted reproductive
technique were enrolled into the study. All patients were
evaluated regularly for at least 3 years after completing ther-
apy. The final analysis comprised 56 women.Combined surgicalemedical treatmentUltramini- or mini-laparotomy was used in all surgical
procedures [29e32]. The principles of reproductive surgery
were strictly followed, thereby minimizing trauma to normal
uterine tissue at all times [33e35]. The microsurgical techni-
que was applied, including magnification, intermittent irriga-
tion, and fine atraumatic instrumentation to decrease blood loss
and prevent postoperative adhesion formation. The adenomy-
otic lesions were meticulously dissected, and careful removal
of all nonmicroscopic lesions was assured by systematic and
thorough palpation of the uterus. The surgical margins were
electrocauterized to destroy all residual lesions, and pelvic
adhesions were excised. To decrease bleeding, a routine local
injection of 10 mL diluted 40e80 vasopressin (20 IU/mL
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administered at the site of adenomyoma. In those cases in
which the uterine cavity was entered, 2-0 poliglecaprone 25
(Monocryl; Ethicon, Somerville, NJ, USA) was used for clo-
sure. The tubal ostia were visualized using the following
strategy: a splint was inserted in both the uterine cavity and the
fimbriae and a retrograde dye (a methylene blue saline solu-
tion) injection was used to demonstrate the os of the bilateral
tubal ostia when accidentally opening the uterine cavity, so as
to avoid iatrogenic injuries. Horizontal sutures followed by
locking sutures were used to close the myometrium, leaving as
little dead space as possible. The serosa was closed with
a continuous inverting suture of 5-0 poliglecaprone 25
(Monocryl; Ethicon) to minimize a raw surface on the uterus.
Finally, copious peritoneal irrigation with a 1:10,000 dilution
of heparin-containing lactated Ringer’s solution was used to
clean debris and blood clots within the abdominal cavity.
All patients received a six-course monthly regimen of
GnRH agonist therapy (Leuplin-Depot; Takeda Pharmaceuti-
cals, Osaka, Japan) postoperatively. The first dose was given to
all patients at the beginning of the first postoperative menstrual
cycle. Postoperative, rather than preoperative administration of
GnRH agonist was chosen to facilitate the intraoperative
identification of adenomyotic lesions and to suppress pro-
gression of residual lesions postoperatively.Assessment of severity of dysmenorrhea and
menorrhagiaTable 1
Clinical characteristics of the patients who were analyzed.
n ¼ 56
Age (mean  SD) 38.3  4.6 years
Body mass index (mean  SD) 21.0  2.0
Parity
0 22 (39.3%)
1 30 (53.6% )
2 4 (7.1%)
Baseline VNRS-6 (mean  SD) 3.96  0.41
Baseline AUS (mean  SD) 2.71  1.03
Baseline menorrhagia scores (mean  SD) 3.73  0.98
Anemia 46 (82.1%)
Preoperative serum level of CA125 70.3  32.0 U/mL




Removed adenomyoma weight (mean  SD) 177.6  64.0
Cases with entry into the uterine cavity 17 (30.4%)
AUS ¼ analgesic usage score; CA125 ¼ cancer antigen 125; SD ¼ standard
deviation; VNRS-6 ¼ six-point verbal numeric rating scale.Dysmenorrhea was defined as pelvic pain during, shortly
before, or after menstrual periods. The periods were restricted
to the two most recent attacks of menstruation at the time of
the visit. To evaluate variation in pelvic pain, we used a self-
reported six-point verbal numeric rating scale (VNRS-6).
When using the VNRS-6, the patients were asked to rate their
pain on a scale from 0 to 5, where 0 represented “no pain” and
5 “the worst pain possible”, using whole numbers (6 integers
including zero). Clinical practice of pain scores (analgesic
usage score: AUS) based on analgesic use were also recorded,
with absolutely no analgesics needed scored at 0; an occa-
sional one or two analgesic drugs needed during menstruation
(<1 day) scored at 1; 3 analgesic drugs needed during
menstruation (<3 days) scored at 2; analgesic drugs needed
during the entire course of menstruation scored at 3; analgesic
drugs needed during menstruation and occasionally during
intermenstruation days scored at 4; and, analgesic drugs nee-
ded nearly every day scored at 5.
Menorrhagia was defined as a bleeding episode persisting
for >7 days in each cycle, and a hemoglobin level <10 g/dL
without other causes of anemia. Menorrhagia was graded by
the duration of menses and degree of anemia: no anemia and
menses lasting <4 days was scored at 0; no anemia and
menses lasting for 4e7 days was scored at 1; no anemia
and menses lasting >1 week was scored at 2; anemia and
menses lasting <4 days was scored at 3; anemia and menses
lasting 4e7 days was scored at 4; anemia and menses lasting
> 7 days was scored at 5.Follow-up proceduresAfter completion of GnRH agonist therapy, the patients’
pregnancy rate and outcome were recorded for a period of at
least 3 years.Statistical analysisStatistical analysis was performed using SPSS for Windows
version 11.5 (SPSS Inc., Chicago, IL, USA). Descriptive sta-
tistics (mean value  standard deviation) and (n and %) are
shown in Table 1. The association between dichotomous and
categorical variables was examined with c2 or Fisher’s exact
tests. The Student t test was used to compare means of con-
tinuous variables. Stepwise linear regression models were then
fit, including all of the variables of interest at the same time as
independent variables, to enable us to demonstrate the relative
contribution of each of these variables to the outcome vari-
ables. Significance was set at p < 0.05 for all tests using a two-
tailed a.
Results
A total of 56 women were enrolled for analysis. The
symptoms were significantly improved after this combined
surgicalemedical treatment for uterine adenomyoma. For
example, the VNRS-6 and AUS were significantly reduced
during the follow-up period: VNRS-6 from the baseline of
3.96  0.41 to 0.32  0.46, 0.68  0.78, and 1.27  1.22 at
the end of the 1st year, 2nd year, and 3rd year, respectively
( p < 0.001) and AUS from 2.71  1.03 to 0.29  0.42,
0.50  0.63, and 1.02  0.92 at the end of the first year,
second year, and third year, respectively ( p < 0.001) (Table 1).
Twenty-three (41.1%) patients had 27 clinical pregnancies
after 3 years of follow-up. The outcomes included 13 term
Table 3
Comparison of the demographics and clinical characteristics at baseline
between the women who had or did not have a successful delivery during
follow-up.
Group A Group B p
Women who had
a successful




delivery (n ¼ 41)
Age (mean  SD) 32.1  3.6 40.6  4.1 <0.001
BMI (mean  SD) 19.3  1.6 21.6  2.4 0.002
Baseline VNRS-6
(mean  SD)
3.7  0.5 4.0  0.7 0.09
Baseline AUS
(mean  SD)
2.0  0.5 3.0  1.3 <0.001
Menorrhagia score
(mean  SD)
3.6  1.4 3.8  1.4 0.66
CA125 (mean  SD) 34.4  11.8 83.4  42.5 <0.001
Tumor weight (g) 165.0  63.0 182.2  90.6 0.50
Nulliparity 10 (67%) 12 (29%) 0.01
Location
Anterior 9 (60%) 9 (22%) 0.025
Posterior 5 (33%) 25 (61%)
Fundal 1 (7%) 7 (17%)
Entering cavity 3 (20%) 14 (34%) 0.51
AUS ¼ analgesic usage score; BMI ¼ body mass index; CA125 ¼ cancer
antigen 125; SD ¼ standard deviation; VNRS-6 ¼ six-point verbal numeric
rating scale.
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spontaneous abortions, and one ectopic pregnancy (Table 2).
To report the factors associated with successful live births,
we divided the 56 women into two groups: Group A (n ¼ 15)
containing 13 term infants and two preterm infants, and Group
B (n ¼ 41) containing the others, including the remaining 12
clinical pregnancies. Compared to the women who did not
have a successful delivery, the women who had a successful
delivery had a significantly younger mean age, lower body
mass index, low baseline self-reported VNRS-6 (3.7 vs. 4.0),
low baseline AUS, low preoperative serum level of CA125,
higher proportions of null parity, and an anterior location of
the adenoma (Table 3).
These significant variables during the univariate analysis
were subsequently included in the multivariate linear regres-
sion model. The regression model showed that age and base-
line AUS were independent predictors of successful delivery
during the 3-year follow-up (Table 4). This model accounted
for 56.5% of the total variance related to successful delivery,
and yielded an equation: successful delivery ¼ 2.64 þ
(0.054)  age þ (0.112)  baseline AUS.
Many of the pregnancies (n ¼ 7) ended as elective termi-
nation during the 3-year follow-up, and in order to avoid
a significant bias in predicting future fertility, therefore, these
patients who were treated with elective termination may be
considered as “supposed” successful fertility. Therefore, we
redivided the 56 women into two new groups: Group C
(n ¼ 19) containing 13 term infants, two preterm infants, and
seven elective abortions, and Group D (n ¼ 37) containing the
others, including the remaining five clinical, but definitely
unsuccessful pregnancies. The women who had supposed
successful pregnancies had significantly lower tumor weight
and tended to be nulliparous. The linear regression model
showed that tumor weight alone accounted for 16.1% of the
total variance of supposed successful pregnancies (b¼0.002,
standard error ¼ 0.001, p ¼ 0.002) (Table 5).
Discussion
Adenomyoma (relatively localized characteristics of focal
adenomyosis) is one of the two forms in which adenomyosis
can present, and consists of circumscribed nodular aggregates
of endometrial glands and stroma within the myometrium [2].
Providing those who have adenomyoma with relief fromTable 2
Pregnancy outcomes following combined surgicalemedical treatment of
adenomyoma in patients not using contraception (n ¼ 56) with follow-up
intervals.
1 y 2 y 3 y Total
Term deliveries 7 4 2 13
Preterm deliveries 1 1 0 2
Spontaneous abortions 2 1 1 4
Elective terminations 2 3 2 7
Ectopic pregnancies 0 0 1 1
Pregnancies 12 9 6 27
Follow-up began after completion of gonadotropin-releasing hormone agonist
therapy.severe dysmenorrhea and menorrhagia is the principal goal of
therapy in the current study (mean of the VNRS-6 of the study
population was 3.96, indicating these patients suffered from
severe painful menstruation). All enrolled patients had un-
dergone various kinds of medical treatment before but none of
them achieved satisfactory symptom control. In addition,
many patients had completed childbearing, and therefore
sought definitive therapy. Therefore, hysterectomy has always
been considered the standard treatment for these severely
symptomatic patients with adenomyoma refractory to medical
intervention. However, due to the recent trend toward organ-
preserving surgery and delayed pregnancy, the number of
women diagnosed with adenomyoma who wish to maintain
their uterus is on the rise.
One important study has reported that conservative surgery
for adenomyoma is associated with a favorable reproductive
prognosis [12]. Although medical treatment is always con-
sidered as the first choice for these severely symptomatic pa-
tients with adenomyoma who desire to retain fertility, and the
surgical approach is considered as a more invasive and radical
method, there is still no consensus on the optimal therapeuticTable 4
Results of stepwise multivariate linear regression analysis of the associations






Age 0.054 0.007 0.476 <0.001
Baseline AUS 0.112 0.034 0.089 0.002
AUS ¼ analgesic usage score.
Table 5
Comparison of the demographics and clinical characteristics at baseline be-
tween the women who had or did not have supposed successful pregnancies
during follow-up.





Women who did not
have a supposed
successful
pregnancy (n ¼ 37)
Age (mean  SD) 37.3  4.6 38.8  5.8 0.359
BMI (mean  SD) 21.1  2.3 20.9  2.6 0.868
Baseline VNRS-6
(mean  SD)
3.9  0.7 4.0  0.6 0.858
Baseline AUS
(mean  SD)
2.9  1.5 2.6  1.1 0.545
Menorrhagia score
(mean  SD)
3.6  1.6 3.8  1.3 0.76
CA125 (mean  SD) 80.6  51.0 65.7  38.4 0.234
Tumor weight (gm) 127.1  41.1 199.6  88.6 <0.001
Nulliparity 10 (58.8%) 12 (30.8%) 0.048
Location
Anterior 8 (47.1%) 10 (25.6%) 0.182
Posterior 6 (35.3%) 24 (61.5%)
Fundal 3 (17.6%) 5 (12.8%)
Entering cavity 5 (29.4%) 12 (30.8%) 0.919
AUS ¼ analgesic usage score; BMI ¼ body mass index; CA125 ¼ cancer
antigen 125; SD ¼ standard deviation; VNRS-6 ¼ six-point verbal numeric
rating scale.
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symptoms recur when medication is stopped.
The relationship between infertility and uterine adeno-
myoma is still uncertain, but severe endometriosis indeed
impairs the successful pregnancy rate during assisted repro-
ductive techniques [11]. To make the study population more
consistent, we excluded patients with adenomyoma but
coexistent adenomyosis or pelvic endometriosis and other
pelvic diseases, or undergoing laparoscopic surgery, which has
been mentioned before [28]. The main finding of our study
was that the reproductive performance rate of women (n ¼ 56)
who underwent combined surgicalemedical treatment for
adenomyoma was as low as 41.1% (27 clinical pregnancies in
23 patients), which was lower than that in the study of Fedele
et al (18 clinical pregnancies in 13 of a total 18 patients
enrolled) [12]. In addition, the majority of pregnancies
occurred within the first year after treatment (Table 2), sug-
gesting that these women’s ability to conceive was reduced by
25e33% each year after the completion of therapy. The def-
inite reasons were unknown, but we supposed the following,
including: (1) the relatively older age of this population (mean
age, 38.3 years); and (2) only 60.7% of the 56 women had
previously conceived, which is lower than the 90% of the
general population or even lower than the cumulative preg-
nancy rate of 75.8% of the entire originally enrolled study
population, suggesting the high possibility of subfertility in
this subpopulation. However, the above reasons may be over-
simplifications. Therefore, it was necessary to divide the 56
women into two groups: those that conceived successfully and
those that did not, and look at the demographics and clinical
characteristics of the patients.In further looking for possible factors that affected future
pregnancy, we divided the 56 women into two groups based on
two endpoints: one ended with those that had a successful
delivery and those that did not; and the other ended with those
that conceived successfully and those that did not. Women
who did not have a successful delivery were significantly older
(40.6  4.1 years vs. 32.1  3.6 years, p < 0.001) and had
significantly higher AUS (3.0  1.3 vs. 2.0  0.5, p < 0.001)
than those who did. The regression model proved that age and
baseline AUS were independent predictors of successful de-
livery during the 3-year follow-up (Table 4). In addition, this
model accounted for 56.5% of the total variance related to
future successful delivery. In further evaluating the role of age,
it was interesting to find that all women, without an exception,
who had a successful delivery, were older than 40 years.
One question brought to our attention in this study should
be mentioned: we still failed to answer why the women’s
ability to conceive was reduced by 25e33% each year after
the completion of therapy. In fact, all successful pregnancies
following treatment with GnRH agonist for adenomyosis and/
or adenomyoma and infertility occurred within 6 months,
ranging from 1 to 6 months after discontinuation of medi-
cation [36e39]. This observation may be easily explained by
the possibility of disease recurrence. By contrast, successful
pregnancies after operative therapy for adenomyosis and/or
adenomyoma can occur 30 months (ranging from 3 to 30
months) after complete surgery [2,27,40,41], suggesting that
recurrence could be delayed by the surgical approach.
Therefore, in our study, was the reproductive performance
in women with uterine adenomyoma after surgicalemedical
treatment due to disease recurrence or other variables, such as
age or disease severity? We tried to answer this question. We
divided the 23 women who had clinical pregnancies into two
groups based on two endpoints: one ended with those that
had a successful delivery at the end of the first year and those
that did not; and the other ended with those that conceived
successfully at the end of the first year and those that did not,
and looked at the demographics and clinical characteristics of
the patients (data not shown). It was interesting that the
preoperative serum level of CA125 and the weight of the
removed tumor were associated with successful delivery at
the end of the first year, but none of above variables was
correlated with successful spontaneous conception at the end
of the first year.
Al Jama has reviewed 40 subfertile women with pathology-
proved adenomyosis over a period of 8 years and found that
higher baseline CA125 was significantly reduced post-
operatively, along with the size of the uterus, suggesting that
operative excision of the uterine adenomyoma could reduce
the size of the uterus as well as the level of CA125 in patients
with adenomyosis. However, this study did not look into the
relationship between a low level of baseline CA125 and the
future clinical pregnancy rate [42]. AI Jama also showed the
benefits of surgicalemedical therapy for future clinical preg-
nancy compared to medical treatment alone, because the
3-year cumulative clinical pregnancy rate of 44.4% (8/18) in
patients who underwent surgicalemedical treatment was
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with GnRH agonist alone [42].
Another study has shown the high predictive values of
CA125 to severity of disease, because high CA125 was
correlated to a more severe disease status (revised American
Society for Reproductive Medicine Classification Stage III
and IV) [43]. Furthermore, Harada and colleagues have
shown that a high level of CA125 in women with endome-
triosis seems to be related to concomitant adenomyosis [44].
Finally, a recent study from Patrelli and colleagues has
shown that the serum CA125 level is significantly higher in
patients with ovarian endometriosis and mixed endometriosis
lesions than in those with extraovarian endometriosis lesions,
and there is a significant correlation between CA125 and the
surgical and pathological findings of ovarian and deep
endometriosis [45].
These findings comply with the above-mentioned question:
was the reproductive performance in women with uterine
adenomyoma after surgicalemedical treatment due to disease
recurrence or other variables, such as age or disease severity,
although the location did not affect the fertility rate [45]. In
our study, we also showed that preoperative CA125 was not
correlated with successful spontaneous conception (fertility
rate) at the end of the first year. In addition, a stepwise mul-
tivariate linear regression analysis of the factors associated
with successful delivery also excluded the value of preopera-
tive CA125 level to predict future successful delivery.
We agree that surgicalemedical therapy with conservative
surgery should be considered as a more invasive and radical
therapy for severely symptomatic women with adenomyoma,
but our results seem to indicate clearly that age was the most
important factor correlated with future successful delivery in
these patients, suggesting that only highly selected patients
might benefit from this approach.
The strength of this study is that it may be the study
enrolling the largest population addressing the topic of surgi-
cal intervention for uterine adenomyoma, because we used the
keywords “adenomyoma, surgery, uterine” to search for rela-
ted published articles in PubMed and found no articles with
a population as large as ours. We believe that this report might
be useful as a reference for those women with uterine ade-
nomyoma treated with surgicalemedical therapy.
Some concerns should be mentioned. First, this study
contained interoperator bias, because there were three doctors
involved in this operation. The surgical technique might be
difference among these doctors, and actually, it was also
a fundamental discrepancy in all clinical studies involving the
comparison of surgical outcome if the surgeries were per-
formed by different doctors.
Second, these women might not have been homogeneous,
because the fertility desire might have varied and some might
have tried more aggressively than others to become pregnant,
although we excluded those women who used contraception,
searched for an assisted reproductive technique, or underwent
laparoscopic surgery. We used stepwise multivariate linear
regression analysis to detect the associations between suc-
cessful delivery and demographics and clinical characteristics.All of these might have contributed to some differences in
outcomes. For example, one study has suggested that the
laparoscopic approach provides the best benefits in fertile
patients with symptomatic leiomyoma, compared to the mini-
laparotomy approach [46e49].
Third, this was a single-arm study without comparison and
all women were treated with combination therapy; therefore, it
was not clear whether surgery or medical treatment or com-
bination therapy influenced the future successful pregnancy
and/or delivery rates. Finally, there is still no agreement on the
severity of uterine adenomyoma, and there is no single tool
that can be used to predict this severity. Although we used
many measures, including AUS, tumor size, serum CA125
level, and pain score (VNRS-6), none of them really reflected
the patients’ situation. Analgesic use might be a reliable in-
dicator of disease severity [50], because traditionally, medi-
cation use is often delayed until the patient cannot tolerate the
pain [33]. That is why we found that only AUS, in addition to
age, could predict the successful delivery rate.
In conclusion, younger age and lower baseline AUS are
strong predictors for future successful delivery when women
with uterine adenomyoma undergo combined surgicale
medical treatment. The combination of conservative surgery
and GnRH agonist treatment should be used with caution with
older women who want to preserve their future fertility.
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